Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
Status:
Terminated
Trial end date:
2014-02-22
Target enrollment:
Participant gender:
Summary
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor. Infusing irradiated donor
lymphocytes into the patient may help the patient's immune system kill tumor cells. Giving
sunitinib together with irradiated donor lymphocytes may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving sunitinib together with irradiated
donor lymphocytes works in treating patients with metastatic kidney cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborators:
National Cancer Institute (NCI) Rutgers Cancer Institute of New Jersey